Dipchand Nishar - Guardant Health Independent Director

GH Stock  USD 20.63  2.67  14.87%   

Director

Mr. Dipchand V. Nishar is Independent Director of the Company. Mr. Nishar has served as a member of our board of directors since October 2018. Mr. Nishar has served as a Senior Managing Partner of SoftBank Investment Advisers Inc. since June 2015 and as a member of the board of directors of TripAdvisor, Inc. since September 2013, in addition to currently serving on the boards of directors of several private companies. Previously, Mr. Nishar served on the OPower, Inc. board of directors from August 2013 to June 2016. He served as Vice President, Products at LinkedIn Corporation from January 2009 to May 2011 and as Senior Vice President from May 2011 to October 2014. Prior to that, Mr. Nishar served in several roles, including as the senior director of products for the AsiaPacific region at Google Inc. from August 2003 to January 2009 since 2018.
Tenure 6 years
Professional MarksMBA
Address 3100 Hanover Street, Palo Alto, CA, United States, 94304
Phone855 698 8887
Webhttps://guardanthealth.com
Nishar holds an M.B.A. degree from Harvard Business School, an M.S. degree in Electrical Engineering from the University of Illinois, UrbanaChampaign, and a B. Tech degree from the Indian Institute of Technology.

Guardant Health Management Efficiency

The company has Return on Asset (ROA) of (0.1764) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1764. This is way below average. Likewise, it shows a return on total equity (ROE) of (4.3813) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to -0.37. The current Return On Assets is estimated to decrease to -0.28. As of now, Guardant Health's Fixed Asset Turnover is increasing as compared to previous years.
The company reports 1.35 B of total liabilities with total debt to equity ratio (D/E) of 4.32, which implies that the company may not be able to produce enough cash to satisfy its debt commitments. Guardant Health has a current ratio of 6.06, indicating that it is in good position to pay out its debt commitments in time. Debt can assist Guardant Health until it has trouble settling it off, either with new capital or with free cash flow. So, Guardant Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guardant Health sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guardant to invest in growth at high rates of return. When we think about Guardant Health's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Prattipati LaxminarainMicrobot Medical
59
Aviel ShapiraMedigus Ltd ADR
61
Doron BirgerMedigus Ltd ADR
66
Oded YatzkanMedigus Ltd ADR
49
Yair RabinovitchMedigus Ltd ADR
67
John CardisEdwards Lifesciences Corp
73
Scott BurellMicrobot Medical
52
Paul LaVioletteEdwards Lifesciences Corp
63
Anat NaschitzMedigus Ltd ADR
N/A
Efrat VenkertMedigus Ltd ADR
46
Yoseph BornsteinMicrobot Medical
65
Solomon MayerMicrobot Medical
62
Leslie HeiszEdwards Lifesciences Corp
60
Ramona SequeiraEdwards Lifesciences Corp
55
Yair RabinowitchMedigus Ltd ADR
71
Nicholas ValerianiEdwards Lifesciences Corp
64
Yuval YanaiMedigus Ltd ADR
65
Steven LorangerEdwards Lifesciences Corp
69
Wesley SchackEdwards Lifesciences Corp
74
Jeremy StarkweatherMedigus Ltd ADR
42
Barbara McNeilEdwards Lifesciences Corp
74
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 1373 people. Guardant Health (GH) is traded on NASDAQ Exchange in USA. It is located in 3100 Hanover Street, Palo Alto, CA, United States, 94304 and employs 1,768 people. Guardant Health is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Guardant Health Leadership Team

Elected by the shareholders, the Guardant Health's board of directors comprises two types of representatives: Guardant Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardant. The board's role is to monitor Guardant Health's management team and ensure that shareholders' interests are well served. Guardant Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardant Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
AmirAli Talasaz, President COO, Director
Richard Lanman, Chief Medical Officer
Marcel Roche, Vice President - Finance
Ian Clark, Lead Independent Director
Leena DasYoung, General Manager,Chief LUNAR Officer
John Saia, Chief Secretary
DEREK BERTOCCI, CFO
Terilyn Monroe, Chief Officer
Craig MD, Chief Officer
Andy Ament, VP Operations
Kumud Kalia, Chief Officer
Michael Bell, Chief Officer
Michael Wiley, Chief Legal Officer
Aaref Hilaly, Independent Director
Darl Moreland, Senior Quality
Jennifer Higgins, Vice Affairs
Dipchand Nishar, Independent Director
Christopher Freeman, Chief Officer
Helmy Eltoukhy, CoCEO CoFounder
Mark Jacobstein, Chief User Engagement Officer
Bahija Jallal, Director
Stanley Meresman, Independent Director
Lynn Lewis, IR Contact Officer
Darya Chudova, VP Technology
Samir Kaul, Independent Director

Guardant Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Guardant Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Guardant Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Guardant Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Guardant Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Guardant Health Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.
Note that the Guardant Health information on this page should be used as a complementary analysis to other Guardant Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Guardant Stock analysis

When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bonds Directory
Find actively traded corporate debentures issued by US companies
Money Managers
Screen money managers from public funds and ETFs managed around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Guardant Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.28)
Revenue Per Share
5.036
Quarterly Revenue Growth
0.222
Return On Assets
(0.18)
Return On Equity
(4.38)
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.